Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

Prostate. 1999 Jan 1;38(1):73-8. doi: 10.1002/(sici)1097-0045(19990101)38:1<73::aid-pros9>;2-v.


Background: A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific PSMA peptides (PSM-P1 and -P2). This report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who were evaluated and reported as a group.

Methods: All subjects received six infusions of DC pulsed with PSM-P1 and -P2 at six week intervals. Clinical monitoring was conducted pre-, during, and post- phase II study. Data collected include: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint scan, chest x-ray, as well as assays to monitor cellular immune responses.

Results: Six partial and two complete responders were identified in the phase II study based on NPCP criteria, plus 50% reduction of prostate-specific antigen (PSA), or resolution in previously measurable lesions on ProstaScint scan.

Conclusions: Over 30% of study participants in this group showed a positive response at the conclusion of the trial. This study suggested that DC-based cancer vaccines may provide an alternative therapy for prostate cancer patients whose disease no longer responds to hormone therapy.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm / administration & dosage
  • Antigens, Neoplasm / therapeutic use
  • Antigens, Surface*
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / therapeutic use*
  • Carboxypeptidases / administration & dosage
  • Carboxypeptidases / therapeutic use*
  • Dendritic Cells
  • Glutamate Carboxypeptidase II
  • HLA-A2 Antigen / administration & dosage
  • HLA-A2 Antigen / therapeutic use*
  • Hormones / therapeutic use
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Radionuclide Imaging
  • Treatment Outcome
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / therapeutic use*


  • Antigens, Neoplasm
  • Antigens, Surface
  • Cancer Vaccines
  • HLA-A2 Antigen
  • Hormones
  • Vaccines, Synthetic
  • Carboxypeptidases
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II